We are 4-Bromophenylboronic acid CAS:5467-74-3 manufacturer and supplier in China, Pls send inquiry of to email@example.com of visit www.nbinno.com our official website should you have any interests
Related News: Taking Minuo Huawei as an example, in 2016, the capacity utilization rate and production-sales ratio of its multiple drug substance varieties reached more than 90%. Therefore, domestic API companies have expanded their production capacity in recent years to meet the growing demand for APIs.(1R,2S)-2-(3,4-Difluorophenyl)cyclopropanaminium (2R)-hydroxy(phenyl)ethanoate China is fast-tracking approval for innovative drugs at home in a bid to offer more and cheaper options to patients, as many in the rapidly aging country struggle to find alternatives to costly treatments sold by multinational pharmaceutical firms for chronic diseases.Ácido 3,5-dibromo-2-metoxibencenocarboxílico CAS:13130-23-9 This is called API. A small amount of the active ingredient has an effect, so only a tiny part of the active ingredient is contained in medicine.1480-65-5 In the context of the new medicine policy, with the development of China’s R & D strength, the number of innovative drugs approved has been blown out, which further strengthened the demand and speed of industrialization of raw materials in China.In 2004, the National Development and Reform Commission, the former Ministry of Health, and the Ministry of Finance jointly formulated and promulgated the Administrative Measures for the Configuration and Use of Large Medical Equipment. This method uses X-ray electronic computer tomography (CT) devices and medical magnetic resonance imaging equipment, digital subtraction angiography X-ray machines of 800 mA or more as the management products of large-scale medical equipment, Purchase and use need to be reported to the provincial health administrative department for approval before approval. However, in recent years, with the comprehensive coverage of medical insurance, such basic medical facilities are being widely popularized, and the relevant implementation rules have directly linked the number of equipment to the number of doctors. Therefore, as the demand for imaging equipment continues to increase, it will have a greater boosting effect on the upstream contrast agent and its raw material market.